Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted precision vascular systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for radial, coronary, and peripheral procedures. Its CorPath system facilitates stent positioning for PCI procedures by allowing a physician to measure, manipulate, and advance devices with robotic precision; and CorPath GRX system enables the precise robotic-assisted control of coronary guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. The company sells its products through direct sales force, as well as through distributor and partnership relationships. It serves vascular, coronary, peripheral vascular, neurointerventional, and structural heart markets. Corindus Vascular Robotics, Inc. is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
Phone+1-508-6533335
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees106
OptionableNot Optionable
Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Frequently Asked Questions
What is Corindus Vascular Robotics' stock symbol?
Corindus Vascular Robotics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVRS."
How were Corindus Vascular Robotics' earnings last quarter?
Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) released its earnings results on Tuesday, August, 7th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.05) by $0.01. The medical equipment provider had revenue of $1.67 million for the quarter, compared to the consensus estimate of $3 million. View Corindus Vascular Robotics' Earnings History.
When is Corindus Vascular Robotics' next earnings date?
What price target have analysts set for CVRS?
3 brokerages have issued 12-month price objectives for Corindus Vascular Robotics' stock. Their predictions range from $1.00 to $2.00. On average, they anticipate Corindus Vascular Robotics' share price to reach $1.6667 in the next twelve months. This suggests a possible upside of 33.3% from the stock's current price. View Analyst Price Targets for Corindus Vascular Robotics.
What is the consensus analysts' recommendation for Corindus Vascular Robotics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corindus Vascular Robotics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corindus Vascular Robotics.
Has Corindus Vascular Robotics been receiving favorable news coverage?
News headlines about CVRS stock have been trending neutral this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Corindus Vascular Robotics earned a coverage optimism score of 0.4 on InfoTrie's scale. They also assigned press coverage about the medical equipment provider a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Are investors shorting Corindus Vascular Robotics?
Corindus Vascular Robotics saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 13,318,394 shares, an increase of 1.4% from the January 15th total of 13,133,613 shares. Based on an average daily trading volume, of 360,423 shares, the days-to-cover ratio is presently 37.0 days. Currently, 15.9% of the shares of the stock are sold short. View Corindus Vascular Robotics' Current Options Chain.
Who are some of Corindus Vascular Robotics' key competitors?
Some companies that are related to Corindus Vascular Robotics include Theralase Technologies (TLT), Zecotek Photonics (ZMS), InspireMD (NSPR), Bioquell (BQE), Consort Medical (CSRT), Deltex Medical Group (DEMG), Ekf Diagnostics (EKF), Immunodiagnostic Systems (IDH), LiDCO Group (LID), Lucid (LCDX), Medaphor Group (MED), Smith & Nephew (SN) and Verisante Technology (VRS).
Who are Corindus Vascular Robotics' key executives?
Corindus Vascular Robotics' management team includes the folowing people:
- Mr. Mark J. Toland, CEO, Pres & Director (Age 49)
- Mr. David W. Long, CFO, Sr. VP, Sec. & Treasurer (Age 49)
- Mr. Tal Wenderow, Co-Founder and Exec. VP of International & Bus. Devel.
- Mr. Douglas Teany, Chief Operating Officer
- Ms. Nora Dutta, VP of HR
Who are Corindus Vascular Robotics' major shareholders?
Corindus Vascular Robotics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Millennium Management LLC (3.71%), Nomura Holdings Inc. (0.66%), Barclays PLC (0.20%), Virtu Financial LLC (0.04%), HRT Financial LLC (0.03%) and Jane Street Group LLC (0.02%). Company insiders that own Corindus Vascular Robotics stock include Healthcor Management, LP, Louis A Cannon and Philips Nv Koninklijke. View Institutional Ownership Trends for Corindus Vascular Robotics.
Which institutional investors are selling Corindus Vascular Robotics stock?
Which institutional investors are buying Corindus Vascular Robotics stock?
CVRS stock was acquired by a variety of institutional investors in the last quarter, including Barclays PLC, Nomura Holdings Inc., Virtu Financial LLC, Millennium Management LLC, HRT Financial LLC and Jane Street Group LLC. Company insiders that have bought Corindus Vascular Robotics stock in the last two years include Healthcor Management, LP and Louis A Cannon. View Insider Buying and Selling for Corindus Vascular Robotics.
How do I buy shares of Corindus Vascular Robotics?
Shares of CVRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corindus Vascular Robotics' stock price today?
One share of CVRS stock can currently be purchased for approximately $1.25.
How big of a company is Corindus Vascular Robotics?
Corindus Vascular Robotics has a market capitalization of $239.15 million. Corindus Vascular Robotics employs 106 workers across the globe.
What is Corindus Vascular Robotics' official website?
How can I contact Corindus Vascular Robotics?
Corindus Vascular Robotics' mailing address is 309 Waverley Oaks Rd Ste 105, WALTHAM, MA 02452-8451, United States. The medical equipment provider can be reached via phone at +1-508-6533335.
MarketBeat Community Rating for Corindus Vascular Robotics (NYSEAMERICAN CVRS)
MarketBeat's community ratings are surveys of what our community members think about Corindus Vascular Robotics and other stocks. Vote "Outperform" if you believe CVRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
